Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label ...

Sage Therapeutics’ shares jumped over 45% to $8.09 in after-hours on Friday, after the company confirmed that biotech major ...

South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...

The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% ...

Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the ...

Mountainfield Venture Partners and Keymed Biosciences launch Timberlyne Therapeutics with $180 million in series A funding.

Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named ...

US pharma giant Pfizer today announced positive top-line results from its pivotal Phase III CREST trial evaluating sasanlimab ...

US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...

USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million ...

Intellia Therapeutics, a US gene editing company developing CRISPR-based therapies, announced late Thursday its strategic ...

The FDA approved 50 novel drugs in 2024, including 18 biosimilars, with many targeting rare diseases and offering ...